🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Stocks - Dow Racks up Gains on Fed Stimulus Hopes, Progress on Covid-19 Drug

Published 04/29/2020, 03:55 PM
Updated 04/29/2020, 04:03 PM
© Reuters.
US500
-
GILD
-
GOOGL
-
AAPL
-
AMZN
-
CL
-
IXIC
-
META
-
GOOG
-

By Yasin Ebrahim 

Investing.com - The Dow rallied on Wednesday as Federal Reserve Chairman Jerome Powell stoked hopes of more stimulus and a positive update on a potential drug to treat Covid-19 patients lifted sentiment.

The {{169|Dow Jones Industrial Average}} rose 2.2%, the S&P 500 added 2.7%, while the Nasdaq Composite gained 3.6%.

"It may well be the case that the economy will need more support from all of us if the recovery is to be a robust one," Powell said, following the Fed's indication to keep its benchmark rate within a 0% to 0.25% range.

"The committee expects to maintain this target range until it is confident that the economy has weathered recent events and is on track to achieve its maximum employment and price stability goals," the Fed said Wednesday.    

Many have attributed the central bank’s efforts to prop up the economy to the recent surge in the broader market since the March 23 low.

Ahead of the Fed decision and remarkets from Powell, the broader market had already racked up gains following positive news on Gilead's potential Covid-19 drug.

Gilead Sciences (NASDAQ:GILD) said a clinical trial evaluating its drug remdesivir in coronavirus patients had met its primary goal, sending its shares nearly 7% higher.

"The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir,” Gilead Chief Medical Officer Merdad Parsey said in a statement.

Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, said he was told data from the trial showed a "clear cut positive effect in diminishing time to recover."

The drug is expected to gain approval from the Federal Drug Administration for emergency use as soon as Wednesday.

With parts of the economy beginning to reopen, investors were reminded about the pandemic's impact on the economy as U.S. economic growth contracted at an annual rate of 4.8% in first quarter of the year.

FAANG stocks, meanwhile, clawed back some of their losses from a day earlier after Google-parent Alphabet (NASDAQ:GOOGL) reported earnings that were better than feared. Facebook (NASDAQ:FB), which is set to report after the closing bell today, was up nearly 6%, while Amazon (NASDAQ:AMZN) was up more than 2% and Apple (NASDAQ:AAPL) gained more than 3%.

Energy, meanwhile, also supported the broader market rally, underpinned by a jump in oil prices owing to a smaller-than-expected bid in weekly U.S. crude inventories.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.